A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects

NCT07585383 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: KR23248
DRUG: Matching Placebo

Sponsor

Jiangxi Kvvit Pharmaceutical Co., Ltd.